ZOMORPH 200 MG — DIN 02254220
MORPHINE SULFATE : 200 MG · ETHYPHARM INC · CAPSULE (SUSTAINED-RELEASE) · wholesale supply in Canada
Health Canada status: APPROVED
What is ZOMORPH?
ZOMORPH 200 MG contains MORPHINE SULFATE : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02254220, held by ETHYPHARM INC, supplied as CAPSULE (SUSTAINED-RELEASE) for ORAL administration. Health Canada currently lists it as approved, status dated 05-Jul-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is ZOMORPH used for?
Symptomatic relief of moderate to severe pain requiring prolonged use of an opioid analgesic for several days or more. Not interchangeable with other slow-release morphine preparations.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Morphine cost around the world?
Morphine is listed on 5 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Morocco publishes a PPV (public price); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 13 | 80 | AUD███.██ |
| United Kingdom | hospital | 11 | 11 | GBP███.██ |
| Morocco | PPV (public price) | 4 | 8 | MAD███.██ |
| South Africa | single exit price | 8 | 8 | ZAR███.██ |
| United States | acquisition | 2 | 2 | USD███.██ |
109 pack listings across 38 brand entries and 5 price bases, refreshed 08 Sep 2026. Ranges span every Morphine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Morphine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
23 holders have a Canadian DIN containing Morphine, across 172 DINs, of which 56 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANDOZ CANADA INCORPORATED | 19 | 12 | MORPHINE HP 25 - 25MG/ML, MORPHINE HP 50, MORPHINE LP EPIDURAL, MORPHINE SULFATE INJ 10MG/ML USP, MORPHINE SULFATE INJ 15MG/ML USP, +6 more | Sourceable in Canada |
| ETHYPHARM INC | 15 | 10 | M-EDIAT, M-ESLON, ZOMORPH | Sourceable in Canada |
| PURDUE PHARMA | 23 | 9 | MS CONTIN, MS CONTIN SUPPOSITORIES - 100MG, MS CONTIN SUPPOSITORIES - 200MG, MS CONTIN SUPPOSITORIES - 30MG, MS CONTIN SUPPOSITORIES - 60MG, +6 more | Sourceable in Canada |
| TEVA CANADA LIMITED | 14 | 5 | NTP-MORPHINE SR, RATIO-MORPHINE, TEVA-MORPHINE SR | Sourceable in Canada |
| BGP PHARMA ULC | 5 | 5 | KADIAN | Sourceable in Canada |
| STERIMAX INC | 4 | 3 | MORPHINE SULFATE INJECTION BP, MORPHINE SULFATE INJECTION EPIDURAL | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 3 | 3 | MORPHINE SULFATE INJECTION | Sourceable in Canada |
| PHARMASCIENCE INC | 13 | 2 | PMS-MORPHINE SULFATE, PMS-MORPHINE SULFATE IR, PMS-MORPHINE SULFATE SR 100 MG, PMS-MORPHINE SULFATE SR 15 MG, PMS-MORPHINE SULFATE SR 200 MG, +2 more | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 8 | 2 | MORPHINE SULFATE INJECTION, USP | Sourceable in Canada |
| ENDO OPERATIONS LTD. | 2 | 2 | STATEX | Sourceable in Canada |
| LABORATOIRE ATLAS INC | 2 | 2 | DOLORAL SIROP | Sourceable in Canada |
| STERINOVA INC. | 2 | 1 | MORPHINE SULFATE INJECTION USP | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 200 MG |
|---|---|
| Dosage form | CAPSULE (SUSTAINED-RELEASE) |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in the provided text (mentions strengths 20, 40, 60, 120 and 200 mg). |
| Storage | Not specified in the provided text. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Morphine |
|---|---|
| ATC code | N02AA01 |
| AHFS class | 28:08.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02254220 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2254220 |
| Brand name | ZOMORPH |
| Generic / active ingredient | MORPHINE SULFATE : 200 MG |
| Market authorization holder | ETHYPHARM INC |
| Health Canada schedule | NARCOTICS (CDSA I) |
| ATC code | N02AA01 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N02AA |
| Current status | APPROVED |
| Status date | 05-Jul-2005 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Must be swallowed whole. 60, 120, and 200 mg strengths are for opioid-tolerant patients only. Adjust dose individually based on prior analgesic experience.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to opiates; respiratory depression; acute asthma; cor pulmonale; cardiac arrhythmias; alcoholism; head injury; brain tumour; paralytic ileus; MAO inhibitors; co-ingestion with alcohol.
Warnings and precautions
Swallow whole; crushing or chewing can be fatal. High strengths (60mg+) for opioid-tolerant patients only. Risk of drug dependence and abuse. May impair ability to drive or operate machinery.
Is Morphine in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by JAMP PHARMA CORPORATION, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
56 of 172 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| DOLORAL SIROP | 1 MG | SYRUP | LABORATOIRE ATLAS INC | MARKETED | 00614491 |
| DOLORAL SIROP | 5 MG | SYRUP | LABORATOIRE ATLAS INC | MARKETED | 00614505 |
| KADIAN | 20 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | 02184435 |
| KADIAN | 200 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | 02559722 |
| KADIAN | 100 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | 02184451 |
| KADIAN | 10 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | 02242163 |
| KADIAN | 50 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | 02184443 |
| M-EDIAT | 20 MG | CAPSULE (IMMEDIATE RELEASE) | ETHYPHARM INC | MARKETED | 02320436 |
| M-EDIAT | 5 MG | CAPSULE (IMMEDIATE RELEASE) | ETHYPHARM INC | MARKETED | 02320398 |
| M-EDIAT | 10 MG | CAPSULE (IMMEDIATE RELEASE) | ETHYPHARM INC | MARKETED | 02320428 |
2 · Same class — other molecules in ATC N02AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Morphine | BAR-MORPHINE SR · DOLORAL SIROP · KADIAN · M-EDIAT · +86 more | 172 | 56 | Yes |
| Hydromorphone | APO-HYDROMORPHONE · APO-HYDROMORPHONE CR · BAR-HYDROMORPHONE CR · DILAUDID · +40 more | 85 | 34 | Yes |
| Oxycodone | ACT OXYCODONE CR · APO-OXYCODONE CR · OXY.IR · OXYCODONE · +16 more | 68 | 28 | Yes |
| Codein, Combinations With Psycholeptics | APO-BUTALBITAL-ACETYLSALICYLIC ACID-CAFFEINE-CODEINE-C 1/2 · APO-BUTALBITAL-ACETYLSALICYLIC ACID-CAFFEINE-CODEINE-C 1/4 · FIORINAL-C 1/2 · FIORINAL-C 1/4 · +13 more | 17 | 6 | Yes |
| Oxycodone And Naloxone | TARGIN | 4 | 4 | Yes |
| Codeine, Combinations Excl. Psycholeptics | AXACET-C1/8 · AXISAL-C1/8 · METHOXACET-C 1/8 · METHOXISAL-C 1/2 · +21 more | 25 | 1 | Yes |
| Natural Opium Alkaloids | NUMORPHAN INJECTION 1.5MG/ML · NUMORPHAN SUPPOSITORY 5MG · OPANA ER | 6 | 0 | Not in Canada |
| Opium | OPIUM TEINTURE | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N02A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N02AX | Tapentadol · Tramadol | 41 | 30 |
| N02AJ | Codeine And Acetylsalicylic Acid · Codeine And Paracetamol · Hydrocodone And Ibuprofen · Oxycodone And Acetylsalicylic Acid · Oxycodone And Paracetamol · +1 more | 137 | 21 |
| N02AB | Fentanyl · Pethidine | 105 | 17 |
| N02AE | Buprenorphine | 15 | 4 |
| N02AF | Butorphanol · Nalbufine | 5 | 2 |
| N02AG | Opioids In Comb With Antispasmodics | 3 | 0 |
| N02AD | Pentazocine | 3 | 0 |
| N02AC | Dextropropoxyphene · Dextropropoxyphene, Comb Excl Psycholept | 7 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ZOMORPH called?
The same molecule, Morphine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| MS Contin | Latin | Australia |
| Morphine Juno | Latin | Australia |
| Kapanol | Latin | Australia |
| MS Mono | Latin | Australia |
| Anamorph | Latin | Australia |
| Sevredol | Latin | Australia, Morocco |
| Morphine Phebra | Latin | Australia |
| MOSCONTIN | Latin | Morocco |
| MORPHINE | Latin | Morocco |
| OPIUM CAMPHORATED TINCT | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.